Open AccessStatins and diabetes mellitus: price of collaboration
Author(s) -
А. А. Александров,
Александров Андрей Алексеевич,
M N Yadrikhinskaya,
Ядрихинская Мария Николаевна,
Svetlana Semenovna Kukharenko,
Кухаренко Светлана Семеновна,
O. А. Shatskaya,
Шацкая Ольга Александровна
Publication year - 2012
Publication title -
saharnyj diabet
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.155
H-Index - 12
eISSN - 2072-0378
pISSN - 2072-0351
DOI - 10.14341/2072-0351-5522
Subject(s) - medicine , diabetes mellitus , glycemic , incidence (geometry) , randomized controlled trial , clinical trial , life expectancy , type 2 diabetes mellitus , primary prevention , endocrinology , disease , population , environmental health , physics , optics
It is now well established that clinical use of statins for primary and secondary prevention of cardiovascular complications in patientswith diabetes mellitus (DM) increases life expectancy. At the same time, meta-analysis of major randomized trials shows statins to increaseglycemic levels and incidence of diabetic symptoms, especially in patients at risk for developing glycemic disorders. However,comparison of positive and negative effects of statins suggests prevalence of clinically beneficial factors.